
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AlloStim,Avelumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Merck Group
Deal Size : Undisclosed
Deal Type : Collaboration
Mirror Biologics, Merck KGaA Collaborate on Metastatic Colorectal Cancer
Details : The collaboration aims to conduct a Phase II to evaluate the combination of an experimental immunotherapy drug, AlloStim, and an immune checkpoint inhibitor, Bavencio avelumab from Merck.
Product Name : AlloStim
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
January 08, 2025
Lead Product(s) : AlloStim,Avelumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Merck Group
Deal Size : Undisclosed
Deal Type : Collaboration

Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer
Details : Allostim is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
August 16, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Allostim
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Immunovative (Thailand)
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunotherapy for Advanced Liver Cancer
Details : Allostim is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 02, 2021
Lead Product(s) : Allostim
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Immunovative (Thailand)
Deal Size : Inapplicable
Deal Type : Inapplicable

Immunotherapy for Third Line Metastatic Colorectal Cancer
Details : Allostim is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 23, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Allostim
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Universal Anti-Viral Vaccine for Healthy Elderly Adults
Details : Allostim is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Virus Diseases.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 22, 2020
Lead Product(s) : Allostim
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : Allovax is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 09, 2015

An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects
Details : Allovax is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 07, 2015

Details : Allostim is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 05, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Allostim
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Allostim is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
December 23, 2013
Lead Product(s) : Allostim
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : Allovax is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Head and Neck Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 29, 2013
